Vaxart (MEX:VXRT) Current Accrued Expense: MXN706 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VXRT Vaxart Inc MEX:VXRT
49 GF Score
Price MXN12.00
! 3 Warning Signs
View Full Analysis

What is Vaxart Current Accrued Expense?

Vaxart MEX:VXRT 49 Current Accrued Expense is MXN706 Mil as of Jun. 2026. GuruFocus rates MEX:VXRT with a GF Score™ of 49/100. The stock has 3 warning signs investors should review.

Vaxart's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN706 Mil.

Vaxart's quarterly Current Accrued Expense declined from Dec. 2025 (MXN786 Mil) to Mar. 2026 (MXN618 Mil) but then increased from Mar. 2026 (MXN618 Mil) to Jun. 2026 (MXN706 Mil).

Vaxart's annual Current Accrued Expense increased from Dec. 2023 (MXN18 Mil) to Dec. 2024 (MXN131 Mil) and increased from Dec. 2024 (MXN131 Mil) to Dec. 2025 (MXN786 Mil).

Vaxart Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Vaxart's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Current Accrued Expense Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.73 96.93 17.96 131.20 785.68

Vaxart Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 593.82 756.50 785.68 617.93 705.66
MEX:VXRT
49GF Score
Vaxart Inc MEX:VXRT
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of MXN706 Mil mean?
Vaxart (MEX:VXRT) has a Current Accrued Expense of MXN706 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Vaxart and its competitors.
Is Vaxart's Current Accrued Expense too high?
Vaxart's current Current Accrued Expense is MXN706 Mil. Overall, Vaxart has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Current Accrued Expense compare to ENGN and NTHI?
Vaxart's Current Accrued Expense of MXN706 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Vaxart and its competitors. Vaxart's current Current Accrued Expense is MXN706 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (MEX:VXRT) has a current Current Accrued Expense of MXN706 Mil. The current Current Accrued Expense is MXN706 Mil. Vaxart's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Vaxart (MEX:VXRT), the current Current Accrued Expense is MXN706 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
49GF Score

Get the complete analysis for MEX:VXRT

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN12.00
Price